NICE backs NHS funding for two cannabis-based drugs for firs...

NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.

NICE says 'no' to regular NHS funding for Roche's Tecentriq ...

NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it

NICE numbers at 20: trends in deals

NICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends in deals that play a role in NICE recommendations made.

Blow to Novartis as NICE rejects migraine drug Aimovig again

NICE numbers at 20 – a closer look at cancer

There has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Health and Care Excellence (NICE), has said when it comes to cancer

HAE patients get new option as NICE backs Takeda's Takhzyro

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in